FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study
Rongce Zhao,Jing Zhou,Zehao Zheng,Xinhao Xiong,Qiaoxuan Wang,Shaohua Li,Wei Wei,Rongping Guo
DOI: https://doi.org/10.2147/jhc.s493577
2024-10-28
Journal of Hepatocellular Carcinoma
Abstract:Rongce Zhao, 1, &ast Jing Zhou, 2, &ast Zehao Zheng, 1, &ast Xinhao Xiong, 1 Qiaoxuan Wang, 3 Shaohua Li, 1 Wei Wei, 1 Rongping Guo 1 1 Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 2 Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 3 Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Rongping Guo; Wei Wei, Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China, Email ; Background: For patients with large unresectable hepatocellular carcinoma (HCC), the effectiveness of conventional transarterial chemoembolization (TACE) remains suboptimal, which necessitates the administration of substantial volumes of chemotherapy drugs and lipiodol, thereby increasing the risk of liver failure and other chemotherapy-related complications. Therefore, we devised a strategy of initial hepatic arterial infusion chemotherapy (HAIC) followed by sequential drug-eluting bead TACE (DEB-TACE). In our treatment design, a lower tumor burden after HAIC facilitated complete embolization of tumor vasculature, and the use of less amount of embolic agents reduced the incidence of liver failure and embolization syndromes. Methods: This retrospective study evaluated consecutive patients with unresectable large HCC with a maximum tumor diameter of ≥ 7 cm who received FOLFOX-HAIC combined with sequential DEB-TACE from April 2019 to February 2024. Efficacy was evaluated using the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS); and safety was assessed using the frequency of key adverse events (AEs). Results: Among the 76 patients included, the median maximum tumor diameter was 12.4 cm (range, 7.0– 23.4 cm). The overall ORRs based on mRECIST and RECIST 1.1 criteria were 94.1% and 51.5%, respectively. The median OS was 28.1 months (95% CI, 22.7– 33.4), and the median PFS was 11.7 months (95% CI, 7.7– 15.8). All patients experienced AEs, but only 18.4% experienced grade 3 or 4 AEs, there was no treatment-related mortality. Conclusion: In this single-center, retrospective study, our results suggested that FOLFOX-HAIC with sequential DEB-TACE demonstrated promising efficacy and safety for patients with unresectable HCC with a maximum tumor diameter of ≥ 7 cm. Keywords: large unresectable hepatocellular carcinoma, hepatic arterial infusion chemotherapy, drug-eluting bead transarterial chemoembolization, sequential Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and is the third leading cause of cancer-related deaths worldwide. 1 Approximately 80% of HCC cases worldwide are in developing countries, 2,3 where HCC surveillance is not widely applied. Consequently, most patients in these areas with the highest risk of HCC are initially diagnosed with large tumors. 4 However, most large HCC cases are not suitable candidates for surgical resection because of insufficient residual liver volume, insufficient surgical margins, or macrovascular invasion. 5 The Barcelona Clinic Liver Cancer (BCLC) guidelines advocate the use of transarterial chemoembolization (TACE) as a therapeutic strategy for patients with unresectable HCC. 6 However, the effectiveness of TACE is often suboptimal in patients with large HCC tumors, 7,8 which have abundant extrahepatic collateral arteries, making it difficult to perform complete embolization. In addition, the use of a large amount of embolization agents may cause serious adverse events (SAEs), such as hepatic dysfunction, postembolization syndrome, and ectopic embolization. 9,10 Hepatic arterial infusion chemotherapy (HAIC) exerts its antitumor effect through the continuous infusion of high concentrations of chemotherapeutic agents. 11 In recent years, several studies have demonstrated that HAIC with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) significantly improved the survival of patients with advanced HCC. 12–14 Li et al report -Abstract Truncated-
oncology